[1] Singh N, Armstrong DG, Lipsky BA. Preventing foot ulcers in patients with diabetes. JAMA.2005;293(2):217-228.[2] Consensus Development Conference on Diabetic Foot Wound Care. 7-8 April 1999, Boston, Massachusetts. American Diabetes Association. J Am Podiatr Med Assoc. 1999;89(9):475-483.[3] Miyajima S, Shirai A, Yamamoto S, et al. Risk factors for major limb amputations in diabetic foot gangrene patients. Diabetes Res Clin Pract.2006;71(3):272-279.[4] Faglia E, Clerici G, Clerissi J, et al. Early and five-year amputation and survival rate of diabetic patients with critical limb ischemia: data of a cohort study of 564 patients. Eur J Vasc Endovasc Surg.2006;32(5):484-490.[5] Blumberg SN, Berger A, Hwang L, et al. The role of stem cells in the treatment of diabetic foot ulcers. Diabetes Res Clin Pract.2012;96(1):1-9.[6] Leiker M, Suzuki G, Iyer VS, et al. Assessment of a nuclear affinity labeling method for tracking implanted mesenchymal stem cells. Cell Transplant.2008;17(8):911-922.[7] Kuo YR, Wang CT, Cheng JT, et al. Bone marrow-derived mesenchymal stem cells enhanced diabetic wound healing through recruitment of tissue regeneration in a rat model of streptozotocin-induced diabetes. Plast Reconstr Surg.2011; 128(4):872-880.[8] Lau TW, Sahota DS, Lau CH, et al. An in vivo investigation on the wound-healing effect of two medicinal herbs using an animal model with foot ulcer. Eur Surg Res.2008;41(1):15-23.[9] Elsharawy MA, Naim M, Greish S. Human CD34+ stem cells promote healing of diabetic foot ulcers in rats. Interact Cardiovasc Thorac Surg.2012;14(3):288-293.[10] Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25(4):402-408.[11] Bao P, Kodra A, Tomic-Canic M, et al. The role of vascular endothelial growth factor in wound healing. J Surg Res. 2009; 153(2):347-358.[12] Rivard A, Silver M, Chen D, et al. Am J Pathol. Rescue of diabetes-related impairment of angiogenesis by intramuscular gene therapy with adeno-VEGF.1999;154(2):355-363.[13] Lobmann R, Schultz G, Lehnert H. Proteases and the diabetic foot syndrome: mechanisms and therapeutic implications. Diabetes Care.2005; 28(2):461-471.[14] Kastrup J, Jorgensen E, Fuchs S, et al. A randomised, double-blind, placebo-controlled, multicentre study of the safety and efficacy of BIOBYPASS (AdGVVEGF121.10NH) gene therapy in patients with refractory advanced coronary artery disease: the NOVA trial. EuroIntervention. 2011;6(7): 813-818. |